Ondansetron HCl

CAS No. 99614-01-4

Ondansetron HCl( GR 38032 (hydrochloride) | SN 307 (hydrochloride) )

Catalog No. M19305 CAS No. 99614-01-4

Ondansetron is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 55 Get Quote
25MG 118 Get Quote
50MG 201 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ondansetron HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    Ondansetron is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.
  • Description
    Ondansetron is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GR 38032 (hydrochloride) | SN 307 (hydrochloride)
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    5-HT3
  • Research Area
    Cancer|Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    99614-01-4
  • Formula Weight
    329.82
  • Molecular Formula
    C18H19N3O·HCl
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.CN1C2=CC=CC=C2C2=C1CCC(CN1C=CN=C1C)C2=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Pinelli A, et al. Eur J Pharmacol, 1997, 340(2-3), 111-119.
molnova catalog
related products
  • p-Benzoquinone

    p-Benzoquinone is a superoxide scavenger. p-Benzoquinone is a toxic metabolite found in human blood.

  • BI-0474

    BI-0474 is a potent KRASG12C inhibitor that inhibits GDP-KRAS::SOS1 protein-protein interactions with an IC50 value of 7.0 nM.BI-0474 exhibits significant antiproliferative activity against NCI-H358 cells harboring the G12C mutation, and shows significant anti-tumor activity in a non-small cell lung cancer xenograft model.

  • BPTU

    Allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM). Non-nucleotide ligand. Binds receptor outside of the helical bundle.